Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirjam T Epping

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The International Journal of Biochemistry & Cell Biology|September 4, 2008
Molecular basis of the anti-cancer effects of histone deacetylase inhibitorsMirjam T Epping, René Bernards
Cancer Research|November 17, 2006
A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancerMirjam T Epping, René Bernards
Molecular Cancer Research : MCR|October 22, 2009
UNC45A confers resistance to histone deacetylase inhibitors and retinoic acidMirjam T Epping, Lars A T Meijer, Johannes L Bos, et al.
Cell|September 24, 2005
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signalingMirjam T Epping, Liming Wang, Michael J Edel, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2007
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitorsMirjam T Epping, Liming Wang, Jane A Plumb, et al.
Nature Cell Biology|December 21, 2010
TSPYL5 suppresses p53 levels and function by physical interaction with USP7Mirjam T Epping, Lars A T Meijer, Oscar Krijgsman, et al.
Cancer Cell|December 30, 2008
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosisSusan Fotheringham, Mirjam T Epping, Lindsay Stimson, et al.
Cancer Cell|April 7, 2009
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcomeSidong Huang, Jamila Laoukili, Mirjam T Epping, et al.
Blood|July 24, 2009
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cellsVivian G Oehler, Katherine A Guthrie, Carrie L Cummings, et al.
Leukemia & Lymphoma|January 14, 2012
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibitionReinhard Dummer, Marc Beyer, Kenneth Hymes, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The International Journal of Biochemistry & Cell Biology|September 4, 2008
Molecular basis of the anti-cancer effects of histone deacetylase inhibitorsMirjam T Epping, René Bernards
Cancer Research|November 17, 2006
A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancerMirjam T Epping, René Bernards
Molecular Cancer Research : MCR|October 22, 2009
UNC45A confers resistance to histone deacetylase inhibitors and retinoic acidMirjam T Epping, Lars A T Meijer, Johannes L Bos, et al.
Cell|September 24, 2005
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signalingMirjam T Epping, Liming Wang, Michael J Edel, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2007
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitorsMirjam T Epping, Liming Wang, Jane A Plumb, et al.
Nature Cell Biology|December 21, 2010
TSPYL5 suppresses p53 levels and function by physical interaction with USP7Mirjam T Epping, Lars A T Meijer, Oscar Krijgsman, et al.
Cancer Cell|December 30, 2008
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosisSusan Fotheringham, Mirjam T Epping, Lindsay Stimson, et al.
Cancer Cell|April 7, 2009
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcomeSidong Huang, Jamila Laoukili, Mirjam T Epping, et al.
Blood|July 24, 2009
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cellsVivian G Oehler, Katherine A Guthrie, Carrie L Cummings, et al.
Leukemia & Lymphoma|January 14, 2012
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibitionReinhard Dummer, Marc Beyer, Kenneth Hymes, et al.
Pageof 2